Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aldo Morrone

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
Clinical and Experimental Rheumatology|May 19, 2017
Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants todayFilippo Bartalesi, Carlo Scirè, Ana Requena-Méndez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2022
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL StudyPaolo Corradini, Chiara Agrati, Giovanni Apolone, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2017
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical PracticeIlaria Baiardini, Fulvio Braido, Giorgia Molinengo, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 18, 2025
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinomaClaudio Pulito, Sebastiano Vaccarella, Alina Catalina Palcau, et al.
Vaccines|July 2, 2021
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMIRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Eclinicalmedicine|June 10, 2021
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccineRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Vaccines|October 26, 2021
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care WorkersFlaminia Campo, Aldo Venuti, Fulvia Pimpinelli, et al.
Frontiers in Immunology|February 12, 2024
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjectsValentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Clinical and Experimental Rheumatology|May 19, 2017
Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants todayFilippo Bartalesi, Carlo Scirè, Ana Requena-Méndez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2022
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL StudyPaolo Corradini, Chiara Agrati, Giovanni Apolone, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2017
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical PracticeIlaria Baiardini, Fulvio Braido, Giorgia Molinengo, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 18, 2025
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinomaClaudio Pulito, Sebastiano Vaccarella, Alina Catalina Palcau, et al.
Vaccines|July 2, 2021
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMIRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Eclinicalmedicine|June 10, 2021
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccineRaul Pellini, Aldo Venuti, Fulvia Pimpinelli, et al.
Vaccines|October 26, 2021
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care WorkersFlaminia Campo, Aldo Venuti, Fulvia Pimpinelli, et al.
Frontiers in Immunology|February 12, 2024
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjectsValentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Pageof 16